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compared retrospectively: patients evaluated in a pancreatic 
MDC versus outside the MDC. Demographics, region of origin, 
disease stage, and patient retention rates (defined as >3 
encounters for pancreatic cancer), telephone encounters, 
and ED visit counts were collected using electronic health 
records. Cost information was obtained using claims data, 
and compared using Fisher’s Exact Tests. Logistic regression 
compared retention rates between the groups, correcting for 
region of origin, demographics, and disease stage. Cox 
proportional hazard models were used to calculate hazard 
ratios of death. Kaplan-Meier curves compared long-term 
survival between the two groups. 
Results: Between 2008-2010, 252 consecutive MDC patients 
were compared to 764 non-MDC patients (total N = 1100). A 
greater percentage of MDC patients traveled from non-
adjacent states (49 vs 23%, p<0.001) and had more advanced 
disease stages (10, 25, and 23% of MDC patients with 
borderline resectable, locally advanced and metastatic 
disease, respectively, versus 5, 9, and 18% of non-MDC). 
Multivariate analysis revealed that MDC patients had 2.816 
times the odds of being retained over non-MDC patients 
(p<0.001). Total charges per patient were higher for non-MDC 
patients than MDC patients and all cost subcategories were 
higher for non-MDC vs MDC patients except for outpatient 
charges (Table 1). The non-MDC group had a higher adjusted 
hazard ratio for death than the MDC group, trending toward, 
but not reaching statistical significance (HR 1.182, p=0.117). 
The MDC also had a lower rate of symptom telephone calls 
(SS) and ED visits (although NS) than the non-MDC group. At 
three years, overall survival was 20% for both MDC and non-
MDC patients (log rank p=0.845). 
Conclusions: Adjusted for region of origin, MDC patients 
were more likely to continue their care at Johns Hopkins, 
suggesting higher patient satisfaction. Total costs per patient 
were lower for MDC patients, even with a greater retention 
rate. Outpatient costs were higher for MDC patients, 
suggesting that greater outpatient engagement can supplant 
more costly inpatient encounters. Because adverse 
downstream encounters were less frequent, survival 
outcomes were at least similar for both groups, and MDC 
patients had lower costs, these data suggest multidisciplinary 
models offer care of higher value for patients with pancreatic 
cancer.  
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Purpose/Objective: Neoadjuvant chemoradiotherapy 
(NACRT) followed by surgery is the standard of care for 
locally advanced carcinoma rectum. Reassessment for surgery 
is done with an MRI scan 6-8 weeks after completion of 
NACTRT.  
The patients in whom the tumor is still inoperable, are 
usually offered palliative chemotherapy. Many oncologists 
advocate waiting upto 12 weeks for a response assessment 
MRI before declaring the disease unresectable, citing a 
possibility of delayed tumour response to radiotherapy. At 
our institute we treated these patients with further 4cycles 
of chemo and reassessed them for operability.  
Materials and Methods: Patients with locally advanced 
carcinoma rectum assessed to have unresectable disease on 
MRI at presentation received neoadjuvant radiation to a dose 
of 50 Gy in 1.8 to 2 Gy daily fractions with concurrent 
capecitabine chemotherapy 825 mg/m2 daily. A follow up MRI 
was done 6 weeks after completion of NACRT and assessed in 
a joint multidisciplinary meeting. Those with persisting 
unresectable local disease were planned for 4 cycles of 
chemotherapy followed by reassessment imaging for 
resectability. We present the results of the patients with 
poor response to NACTRT having further treated by the 
chemotherapy.  
Results: From Jan 2013 till September 2014, 39 patients with 
unresectable rectal cancer recieving NACRT were still found 
to have unresectable disease on MRI. They were planned for 
further chemotherapy with FOLFIRINOX or FOLFOX based 
regimens. Thirty six patients completed at least 4 cycle of 
chemotherapy and one patient defaulted. At the time of 
submission of this abstract, 24 patients had good regression 
of disease which was evident on MRI and 17 (45%) patients 
underwent R0 resection. Seven patients who still had 
unresectable disease and 2 which developed distant 
metastasis were given further palliative chemotherapy. Seven 
patients are scheduled for reassessment after followup 
imaging. One patient was lost to follow-up and 1 died due to 
sepsis. Two patients had complete pathological response. 
Among the 17 successfully operated patients, 8 had received 
FOLFIRINOX while 1 had received FOLFOX and 8 patients 
received CAPOX chemotherapy.  
Conclusions: Achieving margin negative resection in these 
patients is an encouraging starting point for further research 
in this subset. Whether this continued decrease in primary 
tumour volume can be attributed to delayed response to 
radiotherapy or addition of further chemotherapy, or both, is 
yet to be ascertained. Hence for patients with advanced local 
disease not yet in palliative stage, further intensive 
chemotherapy with clinicoradiological follow-up should be 
done to facilitate successful surgical resection.  
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